Last reviewed · How we verify
Concurrent chemotherapy
Concurrent chemotherapy is a Chemotherapy combination regimen Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Various solid tumors (specific indication dependent on chemotherapy agents and trial design). Also known as: CC, Chemotherapy, albumin-bound paclitaxel, cisplatin.
Concurrent chemotherapy administers multiple cytotoxic chemotherapy agents simultaneously or in close temporal proximity to enhance tumor cell death.
Concurrent chemotherapy administers multiple cytotoxic chemotherapy agents simultaneously or in close temporal proximity to enhance tumor cell death. Used for Various solid tumors (specific indication dependent on chemotherapy agents and trial design).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Concurrent chemotherapy |
|---|---|
| Also known as | CC, Chemotherapy, albumin-bound paclitaxel, cisplatin |
| Sponsor | Sun Yat-sen University |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Concurrent chemotherapy combines two or more chemotherapy drugs given at the same time or overlapping schedules to achieve synergistic cytotoxic effects against cancer cells. This approach may improve response rates compared to sequential or single-agent chemotherapy by targeting multiple pathways of cell division and DNA replication simultaneously. The specific mechanism depends on the chemotherapy agents used and their individual modes of action.
Approved indications
- Various solid tumors (specific indication dependent on chemotherapy agents and trial design)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Mucositis
- Diarrhea
- Alopecia
- Fatigue
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (PHASE1)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma (PHASE2)
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Concurrent chemotherapy CI brief — competitive landscape report
- Concurrent chemotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Concurrent chemotherapy
What is Concurrent chemotherapy?
How does Concurrent chemotherapy work?
What is Concurrent chemotherapy used for?
Who makes Concurrent chemotherapy?
Is Concurrent chemotherapy also known as anything else?
What drug class is Concurrent chemotherapy in?
What development phase is Concurrent chemotherapy in?
What are the side effects of Concurrent chemotherapy?
Related
- Drug class: All Chemotherapy combination regimen drugs
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Various solid tumors (specific indication dependent on chemotherapy agents and trial design)
- Also known as: CC, Chemotherapy, albumin-bound paclitaxel, cisplatin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing